Participating Companies


Abide Tx
Serine hy­dro­lase-tar­get­ed ther­a­peu­tics har­ness­ing the en­do­cann­abi­noid sys­tem to ad­dress neu­ro­log­i­cal and pain di­s­or­ders w. limit­ed or no treat­ment op­tions. Ph 2: Tourette Syn­drome on­go­ing with da­ta... [more in­for­ma­tion]
Affimed N.V. [AFMD] US$222 MM MCap
Mo­d­u­lar ROCK™plat­form en­abling mul­ti-spe­cif­ic NK / T-cell bi-and tri-spe­cif­ic Abs. Aug 2018 deal with Ge­nen­tech ($96M up­front / $5B po­ten­tial) to de­vel­op NK-cell en­gager-based ther­a­peu­tics through... [more in­for­ma­tion]
Anavex Life Sciences Corp. [AVXL] US$86 MM MCap
The lead com­pound ANAVEX2-73 re­ceived or­phan drug desig­na­tion from the FDA in Rett Syn­drome, with Ph 2 trial ini­ti­at­ing 1H2018. 2-73 is a small-molecule ac­ti­va­tor of the sig­ma-1 re­cep­tor which has... [more in­for­ma­tion]
Catalyst Pharmaceuticals, Inc. [CPRX] US$268 MM MCap
Fir­dapse ap­proved in Nov 2018 for Lam­bert-Ea­ton Myas­thenic Syn­drome (LEMS) - 2 pos­i­tive Ph 3s com­plete, po­ten­tial launch ear­ly '19. Ad­dl on­go­ing trials in con­geni­tal myas­thenic syn­dromes (CMS), MuSK... [more in­for­ma­tion]
Flex Pharma, Inc. [FLKS] US$6 MM MCap
Pos­i­tive da­ta in Ph2 ex­plo­ra­to­ry study in MS pa­tients - sta­tis­ti­cal­ly sig­ni­f­i­cant 27.3% re­duc­tion in the fre­quen­cy of cramps/spasms com­pared with con­trol. Ph 2 trials on­go­ing in ALS and... [more in­for­ma­tion]
NeuroRx
De­vel­op­ing first Glx tar­get­ed an­tide­pres­sant to ad­dress sui­ci­dal­i­ty in bipo­lar de­pres­sion. Lead can­di­date, NRX-101 in Ph 2b/3 de­vt (Break­thru Desig­na­tion, SPA and Fast Track Desig­na­tion by FDA) for... [more in­for­ma­tion]
Oryzon Genomics [ORY:MA]
De­vel­op­ing treat­ments for the un­der­ly­ing caus­es of can­cer and CNS dis­eas­es by tar­get­ing ly­sine spe­cif­ic demethy­lase 1 (LS­D1, aka KD­M1A), an epi­ge­net­ic hi­s­tone mod­i­fy­ing en­zyme. Lead CNS com­pound... [more in­for­ma­tion]
PAION AG [PAIOF] US$164 MM MCap
Remi­ma­zo­lam: short-act­ing anes­thet­ic. Ph 3 study in pro­ce­du­ral se­da­tion in US. Safe­ty da­ta in ASA III/IV pa­tients in Ph 3 colonos­copy study and Ph 3 bron­chos­copy study. US fil­ing exp by part­n­er Cos­mo... [more in­for­ma­tion]
Probiodrug AG [PRBGF] US$141 MM MCap
Pos­i­tive da­ta from Ph 2a (SAPHIR) clin­i­cal trial for PQ912, for Alzheimer’s Dis­ease (AD), with study de­sign for Ph 2b core pro­gram de­tailed in April 2018. MOA: first in class small molecule QC... [more in­for­ma­tion]
Savara Inc. [SVRA] US$259 MM MCap
Or­phan lung dis­ease co. Mol­gradex, Ph 3, in­haled GM-CSF: au­toim­mune pul­mo­nary alve­o­lar pro­tei­no­sis (aPAP), Ph 2a: non­tu­ber­cu­lous my­cobac­te­ria (NTM) lung in­fec­tion, and prep for Ph 2a in CF af­fect­ed... [more in­for­ma­tion]
Vericel Corporation [VCEL] US$778 MM MCap
Ad­vanced cell ther­a­py; mar­ket­ing MA­CI (car­ti­lage re­pair) and Epi­cel (skin re­place­mentt) in TAMs of $2b+. Epi­cel mar­ket: $2b+. Re­cord 3Q18 rev­enues of $22.5 M rep­re­sents 58% YOY in­crease. FY gui­dance... [more in­for­ma­tion]
ZAI Laboratory [ZLAB] US$1,320 MM MCap
Zai Lab (Nas­daq: ZLAB) is a Shang­hai-based com­pany fo­cused on on­col­o­gy, au­toim­mune & in­fec­tious dis­eas­es. The Com­pany has a broad pipe­line of 4 late-stage as­sets with rights in greater Chi­na and 3... [more in­for­ma­tion]